Navigation Links
Enanta's Lead NS5A Inhibitor Candidate for HCV, EDP-239, Selected as One of Windhover's Top 10 Infectious Disease Projects to Watch

), potential for new opportunities beyond initial indications and corporate stability."

About the Hepatitis C Virus

Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is spread through direct contact with the blood of an infected person. Hepatitis C increases a person's risk of developing chronic liver disease, cirrhosis, liver cancer and death. Liver disease associated with HCV infection is growing rapidly, and there is an acute need for new therapies that are safer and more effective. Specifically targeted antiviral therapies for HCV, such as NS3/4a protease and NS5A inhibitors, may have the potential to increase the proportion of patients in whom the virus can be eradicated.

About Enanta

Enanta Pharmaceuticals is a research and development company that uses its novel chemistry approach and drug discovery capabilities to create best in class small molecule drugs in the infectious disease field. Enanta is developing novel protease, NS5A, nucleoside(tide) polymerase, and cyclophilin-based inhibitors targeted against the Hepatitis C virus (HCV). Additionally, the Company has created a new class of macrolide antibiotics, called Bicyclolides, which overcomes bacterial resistance. Antibacterial focus areas include overcoming resistance to superbugs, treating respiratory tract infections, and developing intravenous and oral treatments for hospital and community MRSA infections. Enanta is a privately held company headquartered in Watertown, Mass. Enanta's news releases and other information are available on the company's web site at

For Enanta Investor Relations, please contact:
Paul Mellett

For Enanta Public Relations, please contact MacDougall Biomedical Communications:
Kari Watson
508-647-0209 or

SOURCE Enanta Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
2. Modulation of inhibitory output is key function of antiobesity hormone
3. Neurocrine Biosciences Announces Notice of Allowance for Composition of Matter Patent on VMAT2 Inhibitor
4. Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis
5. Ardea Biosciences Announces Data on MEK Inhibitor BAY 86-9766 (RDEA119) to be Presented at 2011 American Society of Clinical Oncology Annual Meeting
6. Pharmacyclics Achieves $7 Million Development Milestone for HDAC Inhibitor, PCI-24781 / S 78454 with Servier
7. S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies
8. Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
9. Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting
10. Reportlinker Adds Global Angiongenesis Inhibitors and Stimulators Industry
11. CalciMedica Initiates Phase I Clinical Trial of First CRAC Channel Inhibitor (CCI) for Psoriasis
Post Your Comments:
(Date:10/9/2015)... Francisco, CA (PRWEB) , ... October 09, 2015 , ... ... a study that aims to better understand the relationship between weight management and the ... frequently and more accurately from participants using an iPhone app. , The uBiome app ...
(Date:10/8/2015)... Washington, USA, and CARDIFF, UK (PRWEB) , ... October 08, 2015 ... ... light-based imaging technology to literally see inside the living brain, providing a new tool ... time. , The work is reported by Woo June Choi and Ruikang Wang of ...
(Date:10/8/2015)... PALM BEACH, Fla. , Oct. 8, 2015 /PRNewswire/ ... leader in synthetic biology, today announced the appointment of ... Head of Environment Sector, succeeding Nir Nimrodi ... Development.  Mr. Vaillancourt will direct Intrexon,s endeavors to generate ... North America , where he held a ...
(Date:10/8/2015)...  Sorrento Therapeutics, Inc. (NASDAQ:  SRNE; Sorrento), a ... and associated pain, announced today that Dr. Henry Ji, President ... the Aegis Capital Corporation 2015 Growth Conference in ... 2015 Growth ConferenceDate:Friday, October 9, 2015Time:10:00 to 10:30 ... Wynn in Las Vegas, NV , ...
Breaking Biology Technology:
... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var ... r in data.results) { first_result = data.results[r]; break; } for (var key in first_result) { //s += ...
... Quarter and Six-Month Results -- NEW YORK, Aug. 19 /PRNewswire-Asia/ -- ... ... ... first_result; // Results are keyed by longUrl, so we need to grab the first one. for ...
... Silence Therapeutics plc (AIM: SLN), a leading international ... partner, Quark Pharmaceuticals, Inc. ("Quark"), has announced the grant ... worldwide license to develop and commercialise QPI-1002, a p53 ... Quark is currently conducting a Phase II ...
Cached Biology Technology:
(Date:10/8/2015)... Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial ... on Thursday, October 22, 2015, after the close ... conference call for analysts and investors at 2:00 ... may discuss forward-looking information. ...
(Date:10/8/2015)... , 8. Oktober 2015 ... global tätiges Unternehmen des Bereiches Tracking, hat ... mit der Gefängnisbehörde Virginias (Department of Corrections ... elektronische Überwachungsdienste für alle Strafen geliefert werden, ... Cassell , Präsident für den Amerikanischen Kontinent ...
(Date:10/8/2015)... , October 8, 2015 ... or the "Company"), a biometric authentication company focused ... of the Wocket® smart wallet announces that revenues ... were approximately $410,000 compared with $113,00 for the ... the 9 months ended September 30, 2015 were ...
Breaking Biology News(10 mins):
... predicts their political opinions on economic redistribution, according ... , a journal of the Association for Psychological ... psychological scientists Michael Bang Petersen of Aarhus ... Santa Barbara believe that the link may ...
... , May 14, 2013 /PRNewswire-iReach/ -- With specialized home ... Alzheimer,s and dementia -- can remain in their homes ... facilities. This is often preferable for the patients themselves ... in-home and visiting caregivers, is now providing specialized dementia ...
... the world, and a core group at Penn, have been ... cells (ILCs). Some researchers liken them to foot soldiers that ... the lung, and the lining of the gut from microbial ... inflammatory disease, when the body,s immune system is too active. ...
Cached Biology News:
... The Precision Slide Table is designed ... double bore design provides maximum force output ... has four sets of stainless steel ball ... Bumpers or self-compensating shock absorbers provide ...
... Serum is obtained from ... from healthy, fasted donors. The ... any way and are maintained ... Total Protein Concentration : ...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling Kit with ... For the generation and purification of ... packaged together for complete cDNA labeling ... be used for performing labeling reactions ...
Biology Products: